Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Abstract

OBJECTIVE:

To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia.

METHODS:

Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study.

RESULTS:

In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects.

CONCLUSIONS:

Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.

• Authors: Douglas L Boggs, Deanna L Kelly, Robert P McMahon, James M Gold, David A Gorelick, Jared Linthicum, Robert R Conley, Fang Liu, James Waltz, Marilyn A Huestis, Robert W Buchanan
• Journal: Schizophrenia research (Schizophr Res) Vol. 134 Issue 2-3 Pg. 207-10 (Feb 2012) ISSN: 1573-2509 [Electronic] Netherlands
• PMID: 22137462 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2011 Elsevier B.V. All rights reserved.

Chemical References

• Cannabinoid Receptor Antagonists
• Piperidines
• Pyrazoles
• Rimonabant

Topics

• Adolescent
• Adult
• Analysis of Variance
• Cannabinoid Receptor Antagonists
• Cognition Disorders (drug therapy, etiology)
• Depression (drug therapy, etiology)
• Double-Blind Method
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Neuropsychological Tests
• Piperidines (therapeutic use)
• Psychiatric Status Rating Scales
• Pyrazoles (therapeutic use)
• Rimonabant
• Schizophrenia (complications, drug therapy)
• Treatment Outcome
• Young Adult